

DWS ESG Biotech LC / DE0009769976 / 976997 / DWS Investment GmbH

Last 05/15/2024 ¹	Region	Branch	Type of yield	Type
278.63 EUR	Worldwide	Sector Biotechnology	reinvestment	Equity Fund

■ DWS ESG Biotech LC
■ Benchmark: IX Aktien Biotechnologie



Risk key figures

SRI 1 2 3 4 5 6 7

Mountain-View Funds Rating²EDA³ 74

Yearly Performance

2023	+8.35%
2022	-1.89%
2021	-3.30%
2020	+9.50%
2019	+48.46%

Master data		Conditions		Other figures	
Fund type	Single fund	Issue surcharge	5.00%	Minimum investment	UNT 0
Category	Equity	Planned administr. fee	0.00%	Savings plan	Yes
Sub category	Sector Biotechnology	Deposit fees	0.00%	UCITS / OGAW	Yes
Fund domicile	Germany	Redemption charge	0.00%	Performance fee	25.00%
Tranch volume	(05/15/2024) EUR 335.81 mill.	Ongoing charges	-	Redeployment fee	0.00%
Total volume	(03/28/2024) EUR 364.61 mill.	Dividends		Investment company	
Launch date	8/16/1999	02.01.2018	0.06 EUR	DWS Investment GmbH Mainzer Landstraße 11-17, 60329, Frankfurt am Main Germany https://www.dws.de	
KEST report funds	Yes	02.10.2017	0.18 EUR		
Business year start	01.10.	04.10.2016	0.15 EUR		
Sustainability type	Ethics/ecology	01.10.2015	0.11 EUR		
Fund manager	Dr. Noushin Irani	01.10.2014	0.03 EUR		

Performance	1M	6M	YTD	1Y	2Y	3Y	5Y	Since start
Performance	+0.92%	+24.17%	+5.14%	+12.23%	+37.35%	+17.77%	+46.72%	+460.02%
Performance p.a.	-	-	-	+12.20%	+17.20%	+5.61%	+7.96%	+7.20%
Sharpe ratio	0.42	2.46	0.54	0.45	0.63	0.08	0.17	0.11
Volatility	18.77%	20.67%	20.13%	18.62%	21.16%	22.49%	24.76%	29.75%
Worst month	-	-5.36%	-5.36%	-8.27%	-8.27%	-16.49%	-16.49%	-36.11%
Best month	-	17.08%	17.08%	17.08%	17.08%	17.08%	17.08%	53.96%
Maximum loss	-4.11%	-11.33%	-11.33%	-13.62%	-15.22%	-32.59%	-33.48%	-

Distribution permission

Austria, Germany

¹ Important note on update status: The displayed date refers exclusively to the calculation of the NAV.

² The Mountain-View Data Fund Rating calculates a comparative ranking for funds using yield, volatility and trend data. For more information visit [MVD Funds Rating](#)

³ Displays the Ethical-Dynamical Ratio calculated according to standard criteria. The maximum value is 100. For more information visit [EDA](#)

DWS ESG Biotech LC / DE0009769976 / 976997 / DWS Investment GmbH

Investment strategy


To achieve this, the fund invests mainly in equities of international companies whose revenues or earnings, as reported in the most recent annual report or other suitable documents of the company, were generated primarily from the biotechnology sector, or whose expenditure was primarily on this sector. Equities of issuers from the health care sector may also be added. When selecting the suitable investments, environmental and social aspects as well as the principles of corporate governance ("ESG standards") are of key importance for the implementation of the fund's sustainable investment strategy.

Investment goal


The fund is actively managed. The fund is not managed in reference to a benchmark. The fund promotes environmental and social characteristics and is subject to the disclosure requirements of a financial product in accordance with article 8(1) of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. More ESG information is available in the sales prospectus and on the DWS website. The objective of the investment policy is to achieve sustained capital appreciation that exceeds the benchmark (No benchmark).

Assessment Structure


Assets




Largest positions



Countries



Branches



Currencies

